Latest & greatest articles for anticoagulation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on anticoagulation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on anticoagulation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for anticoagulation

461. Anticoagulant therapy in the Nordic Countries

Anticoagulant therapy in the Nordic Countries Anticoagulant therapy in the Nordic Countries Anticoagulant therapy in the Nordic Countries Joergensen T, Jespersen J (eds) Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Joergensen T, Jespersen J (eds). Anticoagulant therapy in the Nordic Countries. Danish Institute for Health Services (...) Research (DSI). 1994 Authors' objectives Describe state-of-the-art in the Nordic Countries of the use of vitamin-K antagonists in anticoagulant therapy (ACT). Authors' conclusions Quality assurance programmes for ACT should be developed and implemented in clinical departments as well as in primary care. ACT should be concentrated on fewer hands in the clinical unit. Cooperation and communication between clinical departments, the primary health sector and laboratories should be improved. More patients

Health Technology Assessment (HTA) Database.1994

462. Management of heart failure - IV: anticoagulation for patients with heart failure due to left ventricular systolic dysfunction

Management of heart failure - IV: anticoagulation for patients with heart failure due to left ventricular systolic dysfunction Management of heart failure - IV: anticoagulation for patients with heart failure due to left ventricular systolic dysfunction Management of heart failure - IV: anticoagulation for patients with heart failure due to left ventricular systolic dysfunction Baker D W, Wright R F Authors' objectives To review the effectiveness and associated risks of anticoagulation (...) in patients with heart failure. Searching MEDLINE and EMBASE were searched from 1966 to September 1993 using the search terms given. References from identified articles, textbooks and review articles were also examined. Study selection Study designs of evaluations included in the review Observational studies comparing treated and non-treated patients. Specific interventions included in the review Anticoagulation mainly involving the use of coumarin-based drugs. Participants included in the review Patients

DARE.1994

463. Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group.

Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group. 7906757 1994 03 31 1994 03 31 2015 06 16 0140-6736 343 8896 1994 Feb 26 Lancet (London, England) Lancet Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Anticoagulants in the Secondary Prevention of Events (...) in Coronary Thrombosis (ASPECT) Research Group. 499-503 The use of long-term oral anticoagulant treatment after myocardial infarction remains controversial because of conflicting findings on mortality in previous trials and the increased risk of bleeding associated with anticoagulants. We have carried out a randomised, placebo-controlled, double-blind, multicentre trial in 3404 hospital survivors of myocardial infarction. Eligible patients were randomly assigned to anticoagulant (nicoumalone or phenprocoumon

Lancet1994

464. Prevention of one-year vein-graft occlusion after aortocoronary-bypass surgery: a comparison of low-dose aspirin, low-dose aspirin plus dipyridamole, and oral anticoagulants. The CABADAS Research Group of the Interuniversity Cardiology Institute of The Ne

Prevention of one-year vein-graft occlusion after aortocoronary-bypass surgery: a comparison of low-dose aspirin, low-dose aspirin plus dipyridamole, and oral anticoagulants. The CABADAS Research Group of the Interuniversity Cardiology Institute of The Ne 8101300 1993 08 17 1993 08 17 2015 06 16 0140-6736 342 8866 1993 Jul 31 Lancet (London, England) Lancet Prevention of one-year vein-graft occlusion after aortocoronary-bypass surgery: a comparison of low-dose aspirin, low-dose aspirin plus (...) dipyridamole, and oral anticoagulants. The CABADAS Research Group of the Interuniversity Cardiology Institute of The Netherlands. 257-64 Aspirin, alone or in combination with dipyridamole, is known to prevent occlusion of aortocoronary vein grafts. The benefit of dipyridamole in addition to aspirin remains controversial, and the efficacy and safety of oral anticoagulants for prevention of vein-graft occlusion have not been established. We assessed one-year angiographic vein-graft patency after

Lancet1993

465. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Research Committee of the British Thoracic Society.

Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Research Committee of the British Thoracic Society. 1357297 1992 11 02 1992 11 02 2015 06 16 0140-6736 340 8824 1992 Oct 10 Lancet (London, England) Lancet Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Research Committee of the British Thoracic Society. 873-6 The optimum duration of anticoagulation therapy for deep-vein thrombosis (DVT) and pulmonary embolism (PE) is (...) not clear. We have carried out a multicentre comparison of 4 weeks' and 3 months' anticoagulation in patients admitted to hospital with acute DVT, PE, or both. Of 712 patients enrolled, 358 were assigned 4 weeks' treatment and 354 3 months'. Objective confirmation of the diagnosis was obtained in 71%. PE caused or contributed to death in 7 patients (3 treated for 4 weeks, 4 for 3 months). Adverse effects were uncommon, although 1 patient (4-week group) died of haemorrhage. The numbers of patients whose

Lancet1992

466. Trial of different intensities of anticoagulation in patients with prosthetic heart valves.

Trial of different intensities of anticoagulation in patients with prosthetic heart valves. 2300106 1990 03 06 1990 03 06 2013 11 21 0028-4793 322 7 1990 Feb 15 The New England journal of medicine N. Engl. J. Med. Trial of different intensities of anticoagulation in patients with prosthetic heart valves. 428-32 We compared the efficacy and complications of anticoagulation with warfarin in 258 patients with prosthetic heart valves treated with regimens of "moderate intensity" (prothrombin-time (...) was not statistically significant. We conclude that a moderate anticoagulant effect (prothrombin-time ratio, about 1.5) in patients with a mechanical prosthetic heart valve offers protection equivalent to that of more intensive therapy, but at a significantly lower risk. Saour J N JN Department of Medicine, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia. Sieck J O JO Mamo L A LA Gallus A S AS eng Clinical Trial Comparative Study Journal Article Randomized Controlled Trial United States N

NEJM1990

467. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators.

The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. 2233931 1990 12 11 1990 12 11 2013 11 21 0028-4793 323 22 1990 Nov 29 The New England journal of medicine N. Engl. J. Med. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. 1505-11

NEJM1990

468. Hemostatic effect of tranexamic acid mouthwash in anticoagulant-treated patients undergoing oral surgery.

Hemostatic effect of tranexamic acid mouthwash in anticoagulant-treated patients undergoing oral surgery. 2648144 1989 04 28 1989 04 28 2013 11 21 0028-4793 320 13 1989 Mar 30 The New England journal of medicine N. Engl. J. Med. Hemostatic effect of tranexamic acid mouthwash in anticoagulant-treated patients undergoing oral surgery. 840-3 We carried out a placebo-controlled, double-blind, randomized study of the hemostatic effect of tranexamic acid mouthwash after oral surgery in 39 patients (...) receiving anticoagulant agents because of the presence of cardiac valvular stenosis, a prosthetic cardiac valve, or a vascular prosthesis. Surgery was performed with no change in the level of anticoagulant therapy, and treatment with the anticoagulant agent was continued after surgery. Before it was sutured, the operative field was irrigated in 19 patients with 10 ml of a 4.8 percent aqueous solution of tranexamic acid (an inhibitor of fibrinolysis) and in 20 patients with a placebo solution. For seven

NEJM1989

469. Trial of low-dose aspirin plus dipyridamole versus anticoagulants for prevention of aortocoronary vein graft occlusion.

Trial of low-dose aspirin plus dipyridamole versus anticoagulants for prevention of aortocoronary vein graft occlusion. 2567792 1989 08 03 1989 08 03 2015 06 16 0140-6736 2 8653 1989 Jul 01 Lancet (London, England) Lancet Trial of low-dose aspirin plus dipyridamole versus anticoagulants for prevention of aortocoronary vein graft occlusion. 1-7 In a prospective randomised trial, 249 patients who had aortocoronary vein bypass surgery were assigned either to a platelet inhibitory drug regimen (...) or to standard anticoagulant therapy. Treatment was replaced by placebo in half of the patients in each group after 3 months. The platelet inhibitory drug regimen--very low-dose aspirin combined with dipyridamole--was as effective as standard anticoagulant therapy to prevent early and late graft occlusion. Death, myocardial infarction, and severe bleeding occurred significantly more often in patients receiving anticoagulants, whereas mild drug-related gastrointestinal and cerebral side-effects were more

Lancet1989

470. Randomised comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement.

Randomised comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement. 2897516 1988 07 11 1988 07 11 2015 06 16 0140-6736 1 8597 1988 Jun 04 Lancet (London, England) Lancet Randomised comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement. 1242-5 After tissue heart valve replacement 108 patients were randomised to standard anticoagulant control with rabbit brain thromboplastin (Dade C reagent, therapeutic range 18 (...) % to 8.2% for minor embolism. Haemorrhagic complications were significantly more frequent with standard treatment (15 patients) than with the less intensive regimen (6 patients); and of the 5 patients with major haemorrhagic complications, all were in the standard treatment group, again a significant difference. The less intensive regimen is thus no less effective and safer than standard anticoagulant therapy in patients with tissue heart valve replacement. Turpie A G AG Department of Medicine

Lancet1988

471. Influence of postoperative anticoagulant treatment on patient survival after femoropopliteal vein bypass surgery.

Influence of postoperative anticoagulant treatment on patient survival after femoropopliteal vein bypass surgery. 2895319 1988 05 10 1988 05 10 2015 06 16 0140-6736 1 8589 1988 Apr 09 Lancet (London, England) Lancet Influence of postoperative anticoagulant treatment on patient survival after femoropopliteal vein bypass surgery. 797-9 To examine whether anticoagulants given after autologous saphenous bypass surgery influenced patient survival 119 patients who received such a graft (...) Trial England Lancet 2985213R 0140-6736 0 Anticoagulants Q08SIO485D Phenprocoumon AIM IM Aged Anticoagulants therapeutic use Arterial Occlusive Diseases surgery Austria Clinical Trials as Topic Female Femoral Artery surgery Follow-Up Studies Graft Occlusion, Vascular mortality Humans Male Middle Aged Phenprocoumon therapeutic use Popliteal Artery surgery Postoperative Care Prognosis Random Allocation Reoperation Saphenous Vein transplantation Time Factors 1988 4 9 1988 4 9 0 1 1988 4 9 0 0 ppublish

Lancet1988

472. Is a controlled trial of long-term oral anticoagulants in patients with stroke and non-rheumatic atrial fibrillation worthwhile?

Is a controlled trial of long-term oral anticoagulants in patients with stroke and non-rheumatic atrial fibrillation worthwhile? 2870278 1986 05 01 1986 05 01 2015 06 16 0140-6736 1 8484 1986 Apr 05 Lancet (London, England) Lancet Is a controlled trial of long-term oral anticoagulants in patients with stroke and non-rheumatic atrial fibrillation worthwhile? 788-92 A controlled randomised trial large enough to assess the value of anticoagulating stroke patients in atrial fibrillation would (...) be difficult to conduct in the UK and the results would be applicable to only a small proportion of stroke patients. It would be more worthwhile to organise a trial that also assessed the value of other treatments that are simpler and applicable to all stroke patients. A trial that assessed the value of aspirin and beta-blockers against control in all stroke patients would not cost much more than one restricted to comparing anticoagulants against control in patients with stroke and atrial fibrillation

Lancet1986

473. Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis.

Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis. 2863541 1985 10 16 1985 10 16 2016 11 23 0140-6736 2 8454 1985 Sep 07 Lancet (London, England) Lancet Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis. 515-8 The need for oral anticoagulation in patients with calf-vein thrombosis was examined in a randomised study of 51 patients, of whom 23 received warfarin for 3 months and 28 did not. Both groups received an initial course of heparin (...) with 19 out of 28 (p less than 0.02). The findings indicate that oral anticoagulants should be given to all patients with thrombi that produce symptoms. Treatment for 3 months seems to be sufficient. Lagerstedt C I CI Olsson C G CG Fagher B O BO Oqvist B W BW Albrechtsson U U eng Clinical Trial Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't England Lancet 2985213R 0140-6736 5Q7ZVV76EI Warfarin AIM IM Administration, Oral Aged Clinical Trials as Topic Female Humans Male

Lancet1985

474. A controlled comparison of aspirin and oral anticoagulants in prevention of death after myocardial infarction.

A controlled comparison of aspirin and oral anticoagulants in prevention of death after myocardial infarction. 7050710 1982 10 12 1982 10 12 2013 11 21 0028-4793 307 12 1982 Sep 16 The New England journal of medicine N. Engl. J. Med. A controlled comparison of aspirin and oral anticoagulants in prevention of death after myocardial infarction. 701-8 Although neither aspirin nor oral anticoagulants have been conclusively shown to reduce mortality in patients surviving myocardial infarction, both (...) have been widely used for that purpose. In the present clinical trial we compared the effects of aspirin (0.5 g given three times a day) and oral-anticoagulant therapy. Of 6908 patients considered for entry, 1303 were randomized to anticoagulant (652) or aspirin (651) an average of 11.4 days after the onset of myocardial infarction and were followed for 6 to 59 months (mean, 29 months). There were 65 deaths in the anticoagulant group and 72 in the aspirin group. The number of patients

NEJM1982

475. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis.

Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. 6755255 1983 01 19 1983 01 19 2013 11 21 0028-4793 307 27 1982 Dec 30 The New England journal of medicine N. Engl. J. Med. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. 1676-81 We have previously reported that long-term therapy with warfarin is effective for preventing recurrent venous thromboembolism in patients with proximal-vein thrombosis (...) but that there is an appreciable risk of hemorrhage. To determine whether that risk could be reduced without a loss of effectiveness, we randomly allocated 96 patients with proximal-vein thrombosis to a group receiving less intense anticoagulant therapy, with a mean prothrombin time of 26.9 seconds using the Manchester comparative reagent (corresponding Simplastin time, 15 seconds), or a group given more intense therapy, with a mean Simplastin time of 19.4 seconds (corresponding prothrombin time 41 seconds with the Manchester

NEJM1982

476. A double-blind trial to assess long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Report of the Sixty Plus Reinfarction Study Research Group.

A double-blind trial to assess long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Report of the Sixty Plus Reinfarction Study Research Group. 6107674 1981 01 29 1981 01 29 2015 06 16 0140-6736 2 8202 1980 Nov 08 Lancet (London, England) Lancet A double-blind trial to assess long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Report of the Sixty Plus Reinfarction Study Research Group. 989-94 In a randomised double-blind (...) multicentre clinical trial the effect of continued oral anticoagulant therapy after a myocardial infarction was assessed in a group of patients over 60 years of age. Half of the 878 patients who had been on anticoagulants ever since their primary myocardial infarction received placebos instead of the anticoagulant; the others continued anticoagulant therapy. All were followed for 2 years. The levels of hypocoagulability reached in the group on anticoagulants were such that, of the registered prothrombin

Lancet1980

477. Failure of antiplatelet and anticoagulant therapy to improve patency of grafts after coronary-artery bypass: a controlled, randomized study.

Failure of antiplatelet and anticoagulant therapy to improve patency of grafts after coronary-artery bypass: a controlled, randomized study. 386118 1979 12 27 1979 12 27 2013 11 21 0028-4793 301 18 1979 Nov 01 The New England journal of medicine N. Engl. J. Med. Failure of antiplatelet and anticoagulant therapy to improve patency of grafts after coronary-artery bypass: a controlled, randomized study. 962-6 Fifty patients who underwent aortocoronary saphenous-vein bypass-graft surgery were (...) randomly assigned to one of three groups to determine the effects of antiplatelet or anticoagulant therapy on graft patency. Twenty-four patients served as controls; 13 patients received aspirin (325 mg three times a day) and dipyridamole (75 mg three times a day); and 13 patients received closely regulated warfarin therapy. Medications were begun on the third post-operative day. Six months after surgery, all patients underwent coronary angiography to assess graft patency. There were no statistically

NEJM1979

478. Evidence favoring the use of anticoagulants in the hospital phase of acute myocardial infarction.

Evidence favoring the use of anticoagulants in the hospital phase of acute myocardial infarction. 909566 1977 11 30 1977 11 30 2004 11 17 0028-4793 297 20 1977 Nov 17 The New England journal of medicine N. Engl. J. Med. Evidence favoring the use of anticoagulants in the hospital phase of acute myocardial infarction. 1091-6 Since the last comprehensive review of anticoagulation in acute myocardial infarction four additional randomized control trials have been reported. The overwhelming majority (...) of all trials favored anticoagulation. Rates of thromboembolism were higher in the control, and hemorrhagic complications in the anticoagulated group. Pooling of all randomized control trials gives mean case fatality rates of 19.6% for the control and 15.4% for the anticoagulated group, a relative reduction of 21% (P less than 0.05 or less than 0.001, depending on the analytic method). Five of six randomized control trials reported "no effect" because the difference favoring anticoagulation

NEJM1977